Pharmaceutical

EMA supports Sandoz’s Tysabri biosimilar amid various endorsements

The EMA’s decision marks a further step in the biosimilar’s pathway to potential approval and launch amid an ongoing legal battle.

Jul 25, 2023 - 20:00
EMA supports Sandoz’s Tysabri biosimilar amid various endorsements
The EMA’s decision marks a further step in the biosimilar’s pathway to potential approval and launch amid an ongoing legal battle.
Read the original article

Tags:

Previous Article

“The innovation just explodes”: The role of AI in accelerating biopharma R&D

Next Article

Mirati’s KRAS Inhibitor Krazi Fails to Make It in Europe

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanofi backs development of Graviton’s treatments for serious diseases

Sanofi backs development of Graviton’s treatments for s...

Feb 2, 2024

STAT+: Study proposing microbiome-based cancer diagnostic comes under fire

STAT+: Study proposing microbiome-based cancer diagnost...

Aug 3, 2023

Podcast #5: Doing Digital Deals in Life Sciences | Deal Structure, Terms, and Series Conclusions

Podcast #5: Doing Digital Deals in Life Sciences | Deal...

Jul 24, 2024